Viking Therapeutics, Inc. $VKTX Shares Sold by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC reduced its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 26.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,030 shares of the biotechnology company’s stock after selling 25,135 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Viking Therapeutics were worth $2,428,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in VKTX. Royal Bank of Canada grew its stake in Viking Therapeutics by 13.0% during the 1st quarter. Royal Bank of Canada now owns 347,716 shares of the biotechnology company’s stock worth $8,396,000 after buying an additional 39,886 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Viking Therapeutics in the first quarter valued at about $230,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Viking Therapeutics by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,028 shares of the biotechnology company’s stock worth $11,351,000 after acquiring an additional 6,696 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Viking Therapeutics during the second quarter worth about $196,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of Viking Therapeutics by 29.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 481 shares in the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Viking Therapeutics Price Performance

VKTX opened at $35.41 on Tuesday. The firm has a fifty day moving average price of $32.47 and a 200 day moving average price of $33.70. Viking Therapeutics, Inc. has a 1 year low of $21.23 and a 1 year high of $43.15. The stock has a market cap of $4.10 billion, a P/E ratio of -11.09 and a beta of 0.83.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.49). During the same quarter in the prior year, the firm earned ($0.32) EPS. Equities analysts expect that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

VKTX has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, January 21st. Wolfe Research began coverage on Viking Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Zacks Research upgraded Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 18th. Morgan Stanley reiterated an “overweight” rating and issued a $99.00 target price on shares of Viking Therapeutics in a research report on Thursday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Monday, March 23rd. Four investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.22.

Insiders Place Their Bets

In other Viking Therapeutics news, insider Neil William Aubuchon purchased 4,475 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $33.50 per share, for a total transaction of $149,912.50. Following the completion of the transaction, the insider owned 4,475 shares of the company’s stock, valued at $149,912.50. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 4.10% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non?alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor?beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.